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ABSTRACT 
Oral delivery is the preferred route of administration because it offers several advantages over other routes. However, it is not an effective 
route for the delivery of peptides and proteins because of so many constraints. The small intestine has been shown to be able to transport 
the L-forms of amino acids against a concentration gradient and that they compete for the mechanism concerned. So L-Valine was used as a 
ligand for carrier mediated transport of insulin loaded PLGA nanoparticles. L-valine-conjugated PLGA-nanoparticles were prepared using 
double emulsion solvent evaporation method. The insulin bearing nanoparticles were also studied for size, drug entrapment efficiency, zeta 
potential and polydispersity index, in vitro insulin release. Ex-vivo studies on intestine revealed that conjugated nanoparticles showed 
greater insulin uptake as compared to nonconjugated nanoparticles. In-vivo studies were performed on streptozotocin induced diabetic 
rabbits.  Oral suspension of insulin loaded PLGA nanoparticles reduced blood glucose level from 265.4±8.5 to 246.6±2.4 mg/dl within 4 hrs 
which further decreased to 198.7±7.1 mg/dl value after 8 hrs, The ligand conjugated formulation on oral administration produced 
hypoglycaemic effect within 4 hrs of administration, the hypoglycaemic effect prolonged till 12 hours of oral administration. Simultaneously, 
the insulin concentration in withdrawn samples was also assessed and found that profile of insulin level is in compliance with the blood 
glucose reduction profile. Compared with formulation loaded with the drug, the valine conjugated nanoparticles produced a sustained 
hypoglycaemic response till 12 hrs than 8 hrs. Hence, it is concluded that the L-valine conjugated NPs bearing insulin are the promising 
carrier for the transportation of insulin across the intestine on oral administration 
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INTRODUCTION 
Diabetes mellitus, often referred to simply as diabetes 
(ancient greek: "to pass through urine"), is a syndrome of 
disordered metabolism, usually due to a combination of 
hereditary and environmental causes, resulting in 
abnormally high blood sugar levels (hyperglycemia). 
Diabetes mellitus refers to the group of diseases that lead 
to high blood glucose levels due to defects in either insulin 
secretion or insulin action.1 
Oral delivery is the preferred route of administration 
because it offers several advantages over other routes. It is 
more natural, less invasive, can be self-administered 
(outside the hospital), and is less expensive. However, it is 
not an effective route for the delivery of peptides and 
proteins because of so many constraints. To date, various 
strategies have been developed to achieve an effective oral 
insulin delivery system, including co-administration with 
absorption enhancers.3 or lipid-based carriers as 
liposomes.4 
Protein drugs, such as insulin,  have  traditionally  been  
administered  by  injection  because  of  their  large  
molecular weights and the dependence of their bioactivity 
on structure. However, the oral administration of protein 
drugs has major challenges. To meet these challenges, an 
oral delivery system must protect the drug in the stomach 
from proteolytic enzymes and acid but allow absorption of 
the drug in either the small or large intestine. The target 
site of absorption is the small intestine which  is  typically  
preferred  for  absorption  of  hydrophilic  proteins  due  to  
a  more permeable epithelium than the colon.2  
It was also reported that L-valine conjugated drug 
enhances oral bioavailability of drug implicate the 
oligopeptide transporter as the carrier involved in 
absorption of L-valine combined drug.  
Vishwakarma et al                                                                                         Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):93-101  
ISSN: 2250-1177                                                                                  [94]                                                                                 CODEN (USA): JDDTAO 
Hence, it is aimed to develop L-valine combined PLGA 
nanoparticles bearing insulin for oral administration. The 
PLGA nanoparticles will protect the insulin from its 
degradation in gut and L-valine molecules which are 
attached to the surface of nanoparticles will help insulin 
bearing nanoparticles to transport across intestinal 
membrane.  
The present work aimed at the preparation and evaluation 
of L-valine-combined PLGA-nanoparticles for the oral 
delivery of insulin using target specific Nanoparticles 
bearing insulin. 
MATERIALS AND METHODS 
The drug (human recombinant insulin) was a gift sample 
obtained from Biocon, Bangalore (India). Poly lactic- co- 
glycolic acid (PLGA)(50:50) polymer was obtained as a gift 
sample from SPARC (Sun pharmaceuticals advanced 
research center), Baroda, India. L-valine, Dichloromethane 
(analytical grade), Arlacel 83 were purchased from Sigma 
(St. Louis, USA) and PVA and mannitol were purchased 
from Central Drug House, Mumbai, India.  
Conjugation of polymer with L-valine amino acid 
L-valine was conjugated to PLGA using carbodiimide 
coupling process as reported by Nam and Park (1999). 
Briefly, one gram of PLGA (50:50) having a carboxylic acid 
end group was activated by 9mg of DCC in 3ml of DMSO at 
room temperature for 2hr. The activated PLGA solution 
was slowly dropped into 5mL of DMSO containing 100 mg 
L-valine which had been previously lyophilized at pH 9. 
The reaction was continued for 3 h under constant 
magnetic stirring at room temperature. The PLGA-valine 
conjugate was precipitated by slowly dropping into an 
excess amount of chilled diethyl ether and centrifuged to 
remove precipitate then washed with deionized water, and 
lyophilized. In order to remove completely the residual 
unconjugated valine fraction, the lyophilized PLGA-valine 
conjugate was milled, incubated in deionized water at 37C 
for a day, centrifuged to precipitate water insoluble 
conjugate, filtered and then lyophilized washing process 
was repeated till the complete removal of unconjugated 
valine.12 
Characterization of conjugation 
IR spectroscopy 
Characteristic peaks of valine, PLGA and valine conjugated 
PLGA were analyzed by FTIR (PerkinElmer, Pyrogon 1000) 
IR spectra were recorded on a Perkin-Elmer FTIR-1000 
spectrometer using KBr pellets. (Infrared spectra are 
shown in Fig.1)  
Conjugation efficiency 9 
Conjugation efficiency was determined. About 10 mg of 
accurately weighed lyophilized L-Valine conjugated PLGA 
was dissolved in 2 mL DMSO and incubated for 5 h at room 
temperature with 10 mL of 0.05 N NaOH / 0.5%sodium 
dodecyl sulfate (SDS). 1 mL of the resultant solution  was 
mixed with an equal volume of bicinchoninic acid assay 
(BCA) working solution (prepared by mixing 50 parts of 
Reagent A with 1 part of Reagent B. Mixed the BCA 
Working Reagent until it is light green in colour.) at 60°C 
for 1h and assayed at 562nm spectrophotometrically.  
Conjugation efficiency (%) =
Wt. of protein (µg valine )
Wt. of lyophilized nanoparticle (mg)
× 100 
 
Preparation of insulin loaded Nanoparticles 5, 7 
Nanoparticles were prepared using double emulsion 
solvent evaporation method .The aqueous  Primary 
emulsion was prepared by dissolving 100 mg of Insulin in 
2.5mL of 0.01N HCl (pH 2.8) while oil phase was prepared 
by dissolving 1 g PLGA and 0.25 wt.% Arlacel 83 in a 10mL 
mixture solvent of dichloromethane (DCM) and acetone 
(3:1), then aqueous phase was slowly dispersed in oil 
phase using sonication (lark Innovation, Chennai) for 30 
sec to form w/o emulsion and later this primary emulsion 
was re-emulsified with 100mL aqueous phase consisting of 
stabilizer polyvinyl alcohol (1 g) 70 KDa using sonication 
for 60 secs. The double emulsion was subjected to 
magnetic stirring at 100 rpm for 8 h at 25±1C for 
complete evaporation of DCM and acetone to obtain 
concentrated residue which redispersed in distilled water 
and then purified by ultracentrifugation at 30000 rpm for 
15 min to remove PVA. The NPs so formed were collected, 
washed and freeze dried with cryoprotectants (mannitol). 
Characterization of nanoparticles 
The prepared nanoparticles were characterized for surface 
morphology, particle morphology, particle size, 
entrapment efficiency, zeta potential, and polydispersity. 
Shape and surface morphology 
Scanning Electron Microscopy (SEM) and Transmission 
Electron Microscopy (TEM) were used to characterize the 
shape and surface morphology of the SLN, respectively. In 
SEM (Philips XL 30 Scanning Microscope, Philips, 
Eindhoven, Netherlands), SLN were coated with gold–
palladium alloy (150–250 Å) using a sputter coater before 
analysis. The morphological examination of the 
nanoparticles was also performed using TEM (JEM-200 CX, 
JEOL, and Tokyo, Japan). In case of TEM, SLN samples were 
stained with 2% w/v phosphotungstic acid for 10 s, and 
excess of the solution was drained off using filter paper. 
The grid was allowed to thoroughly dry in air and samples 
were viewed under a transmission electron microscope.  
Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS -PAGE) 
Polyacrylamide gel electrophoresis was performed to 
compare the electrophoretic mobility of insulin before and 
after nanoparticles formulation. In addition, the NPs and 
Con A NPs were centrifuged at 13,000g for 15 min to 
separate insulin from the pelleted-particle fraction from 
the soluble supernatant. The pellet and supernatant were 
analyzed using SDS-PAGE to determine relative amounts of 
insulin associated with each fraction.18 For electrophoresis, 
samples were boiled for 5 min in the presence of sodium 
dodecyl sulfate and -mercaptoethanol. An aliquot of the 
samples, equivalent to 10–100μg of insulin, was 
electrophoresed on a 16% SDS polyacrylamide gel for 1 hr 
at 200 V. Insulin was visualized using silver nitrate staining 
which has a detection limit of 1µg. Molecular weight 
protein standards were used to compare the 
electrophoretic mobility of NPs and unprocessed insulin.  
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Circular Dichroism Study (CD- spectrum) 
Secondary structure of insulin is necessary for its 
bioactivity, therefore its secondary structure integrity was 
analysed by CD Spectrum.  The extracted insulin was 
dissolved in isotonic PBS buffer was analyzed for its 
integrity by CD spectra (Jasco, J-815 Spectropolarimeter, 
UK) at room temperature with scanning speed of 50 
nm/min. The spectra of insulin samples extracted from 
NPs and Con A NPs with concentrations about 10 mM were 
compared with pure insulin. 
Entrapment Efficiency (EE) 8, 10 
EE was determined using acetonitrile extraction method to 
analyze the insulin content within the Nanoparticles. 
Freshly prepared insulin-PLGA-NP suspension (1mL equal 
to 100 IU or 3.6 mg of insulin) was ultracentrifuged for 1 h 
at 4ºC at 50,000 rpm (Ultracentrifuge, HEMLA Lab. 
Germany) in order to isolate the un-entrapped insulin from 
the entrapped insulin. The supernatant was removed and 
nanoparticles sediments were resuspended in water. The 
resuspended solution was ultracentrifuged twice under the 
same conditions. 200µL Acetonitrile was added into the 
sediments and the mixture was vortexed for 5 min. Then, 
800µL of 0.01M HCl was added and vortexed for 2 min. 
After centrifugation at 15,000 rpm (centrifuge) at 4ºC for 
20 min, supernatant was collected for further RP-HPLC 
analysis of insulin by the method discussed previously. 
In–vitro release study 
Preparation of enteric polymer coated capsules 
To protect insulin from harsh environment of stomach, 
insulin loaded NPs and insulin loaded conjugated NPs were 
filled separately in hard gelatin capsules (Capsule No. 5) 
which were coated with enteric polymer Eudragit S 100 
using dip coating. 
In-Vitro Drug Release 
Firstly the dialysis bag (Dialysis membrane MW cut off 12 
kda) was treated by heating in distilled water at 60C for 1 
h.One capsules filled with NPs and conjugated NPs were 
taken in treated dialysis bag and tied both ends of bag, 
which was dipped in 100 mL media. The pH of media was 
changed with respect to time according to following 
schedule.7 
0.1N HCl (pH 1.2) Initial two hours.  At pH 5.5 - 1h,  at pH 
6.8 -2h and at pH 7.5- until the end of the test. The final 
volume in all cases was 100 mL.17 From the medium 1 mL 
of the solution was withdrawn after definite time interval 
then analyzed spectrophotometricaly at 276 nm by UV 
visible spectrophotometer (GBC Cintra 10). 
Thermal stability of encapsulated drug 
Differential Scanning Calorimetry- 
Differential scanning calorimetry (DSC) represents a 
thermoanalytical method that measures the difference in 
the thermal energy required to increase the temperature of 
a sample and a reference with well-defined heat capacity 
as a function of the temperature. Ideally, both the sample 
and the reference are kept at identical temperature, while 
the temperature increases linearly as a function of time. As 
soon as the sample undergoes a physical transformation, 
the heat flow to the sample will be decreased or increased 
relative to the reference, thus, resulting in a DSC signal.14 
In-vivo studies 
 Albino rabbits of either sex weighing 2-2.5 kg were chosen 
for the present studies. All in vivo studies on animals were 
approved by animal ethical committee of the Dr. H. S. Gour 
University, Sagar (MP), India constituted under the 
guidelines of CPCSEA, New Delhi, India through their vide 
letter no. animal eths. Comm./12/82/35 dated 20/22-05-
12. 
Induction of diabetes  
The diabetes was induced in rabbits with single 
intravenous administration of streptozotocin (50 mg/Kg). 
The solution of streptozotocin (50 mg/mL) was made in 
citrate buffer (pH 4.5). Then, the external marginal ear vein 
of the rabbits was cleaned with boiled water with the help 
of the cotton, so that the vein could be visualized easily for 
i.v. administration. The blood sugar level was first 
measured before administering streptozotocin solution to 
animals. The solution of streptozotocin (50 mg/mL) was 
administered intravenously.16 
After 8-10 days of treatment, rabbits with frequent 
urination, loss of weight and blood glucose level higher 
than 250 miligram per deciliter (mg/dL) were selected for 
study. Animals were housed in groups of three (as per the 
permission of animal ethical committee) with free access 
to food and water. Animals were fasted over 24 h before 
starting the test, but water was provided ad-libitum.  Blood 
glucose level of all animals were checked before starting 
experiment. During experimentation standard diet was 
given to the animals of all the groups at 4th h and 12th h.12  
The blood glucose level was monitored using glucose 
oxidase-peroxidase (GOD-POD) method using calorimeter 
(J. Mitra & Co Pvt. Ltd., New Delhi, India) with green filter 
at 510 nm. 
Experimental design 
Rabbits were divided into five groups and each group consists 
of 3 animals and all animals were induced diabetes as per the 
procedure stated above. Group-1: Animals of this group were 
received only plain water without any drug or formulation (control 1). 
Group-2: Animals of this group were administered oral insulin 
powder (20 IU/Kg) (control 2).  Group-3: Animals of this group 
were received insulin (20 IU/Kg) through subcutaneous route.  
Group-4: Insulin loaded NPs equivalent to (20 IU/Kg) weight of 
animals were administered to all animals of this group. Group-5: 
Ligand conjugated NPs bearing insulin equivalent to (20 
IU/Kg) weight of animals were administered orally to all animals 
of group 5. 
Sample collection 
 Blood (1.0 mL) was withdrawn periodically from the 
marginal ear vein of the rabbits of each group into clean 
heparinized eppendorf tubes. Blood samples were kept on ice 
until diagnosis. The same blood samples were used to 
determine blood glucose level as well as insulin level in the 
withdrawn samples. 
Insulin plasma level determination 
The above withdrawn samples were also assessed for 
insulin concentration determination using the HPLC 
method with slight modifications.13 
Instrumentation and chromatographic conditions 
The mobile phase consisted of 0.2 M sodium sulphate 
anhydrous adjusted to pH 2.3 with ortho phosphoric acid 
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and acetonitrile (74:26, v/v), filtered through a 0.45µm 
Nylon membrane filter (Whatman International, 
Maidstone, UK) under vacuum and degassed prior to use. 
The analysis was run at a ﬂow rate of 1.2 mL/min. The 
detector was set at a wavelength of 214 nm. The 
chromatographic separation of the analyte was achieved at 
ambient room temperature with HPLC column was C18 (4.6 
X 250 mm, 5 µm). The injection volume was 20 µL. 
Preparation of Stock and Working Standard Solutions 
A stock standard solution of insulin at 140 µg/mL was 
prepared from human recombinant insulin in PBS pH (7.4). 
The working standard solutions were made in the range of 
3.5–42 µg/mL. The stock solution of methylparaben, as an 
internal standard (I.S.) was prepared at a concentration of 
500 µg/mL in methanol and was further diluted with the 
same diluent to give a working concentration of 15 µg/mL. 
All solutions were stored under refrigeration at 4C prior 
to use.5 
Preparation of calibration standards 
To 80 µL of blank rabbit plasma, 20 µL of working standard 
solutions of insulin of an appropriate concentration was 
added to yield final respective concentrations at range of 
50 to 500 ng/mL of insulin in plasma. 
Sample extraction procedure 
To each of the above mentioned calibration standard, 20 
µL of I.S. solution (15 µg/mL), 50 µL of PBS pH 7.4 and 3 
mL mixture of dichloromethane and n-hexane (1:1, v/v) 
extraction solvent were added. The mixture was vortexed 
for 2 min and centrifuged (Remi, India) at 3,500 rpm for 10 
min. The supernatant was transferred to a reactivial placed 
in a heating block at 40 C, evaporated to approximately 
200 µL under a gentle stream of nitrogen gas, then 200 µL 
of 0.05 M HCl were added for back extraction, and vortexed 
for 2 min. Finally, the remaining organic layer was 
evaporated to dryness under a gentle stream of nitrogen 
and 20 µL of sample was injected into the HPLC column. 
The pharmacokinetic parameters were determined using 
software (kinetical trial version). 
RESULTS  
PLGA was conjugated with L-valine. The molecular 
conjugation of PLGA with hydrophilic drugs, in particular 
peptides and proteins, has been scarcely found in the 
literature. Uncapped and hydrophilic PLGA that has a 
carboxylic acid group at its terminal end, however, can be 
readily conjugated to various drug compounds. L-Valine 
was selected for the conjugation. L-Valine can be 
molecularly dissolved in DMSO, a polar organic solvent, in 
which PLGA could also be dissolved. By using DCC as a 
coupling agent, L-valine was conjugated with PLGA using 
carbodiimide chemistry where DCC was used as coupling 
agent. 
 The conjugation of L-valine with PLGA polymer was 
proved by FTIR. In PLGA, a peak at 3396 cmˉ1 was found 
which indicates the bending of free N-H stretching, peak at 
1749.3 cmˉ1  represents C=O stretch, peak at 1402.7 cmˉ1  
represents N-H bending. In valine-PLGA conjugate, peak at 
1718 cm-1 represents C=O stretch of valine-PLGA 
conjugate, peak at 1211,1185 cmˉ1  represents C-O stretch, 
peak at 1538.3 cmˉ1 represents N-H bending and peak at 
3381/3217 cmˉ1  represents N-H stretch which prove the 
conjugation of NH2 group of L-valine with COOH group of 
PLGA.
  
 
Figure1: IR Spectra of (A) valine (B) PLGA and (C) L-valine combined  PLGA 
 
PLGA (poly lactic co glycolic acid) was used for the 
preparation of nanoparticles (NPs). PLGA with 50:50 
monomers as ratio exhibits faster degradation (about two 
months). In addition, polymers that are end-capped with 
esters (as opposed to the free carboxylic acid) demonstrate 
longer degradation half-lives and molecular weight 17000 
was used in the preparation of nanoparticles. For this 
study uncapped PLGA was used which is having free 
carboxylic acid group (COOH) for the conjugation.
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Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS -PAGE) 
An aliquot of the samples, equivalent to 10–100μg of 
insulin, was electrophoresed on a 16% SDS polyacrylamide 
gel for 1 hr at 200 V. Insulin was visualized using silver 
nitrate staining which has a detection limit of 1µg. 
Molecular weight protein standards were used to compare 
the electrophoretic mobility of NPs and unprocessed 
insulin.
 
 
Figure 2: SDS-PAGE of Insulin. Lane 1:  Molecular marker, Lane 2: Insulin. 
The CD spectrum of insulin in PBS, at (pH 7.4), shows two 
minima at 210 and 224 nm. These results were in close 
agreement with results.15 There was insignificant deviation 
of the negative maximum at about 223 nm for insulin from 
PLGA nanoparticles (Fig.3). 
  
 
Figure 3: CD- Spectra of (a) Insulin from conjugated Nanoparticles, (b) Insulin. 
It was anticipated from the study of in vitro drug release 
profile that the formulation gives no detectable release at 
initial two hours. In vitro release studies of NPs showed a 
percent cumulative drug release of NPs was 48.587.3% 
after 24 h whereas conjugated nanoparticles showed 
cumulative drug release of 45.81±8.7% after 24 h (Fig. 4). 
A significant decline in the percentage cumulative release 
rate of insulin from conjugated nanoparticles was 
observed in comparison to NPs.  
 
 
Figure 4: Cumulative percent drug released at different pH. 
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The SEM and TEM photomicrographs showed the spherical 
morphology of the nanoparticles. TEM was used to 
investigate the shape of NPs. TEM photographs suggested 
that all NPs and NPs of conjugated polymer were spherical 
in shape and in nanometric range. 
  
 
(a)Nanoparticles 
 
(b) Conjugated Nanoparticles 
Figure 5:  SEM image of Insulin loaded Nanoparticles 
 
(a)Nanoparticles                                                 (b) Conjugated Nanoparticles 
Figure 6: Photomicrograph is showing TEM image of insulin loaded 
The entrapment efficiency of NPs was found to be 
50.37±5.9% whereas ligand conjugated NPs showing 
52.02±.1.5% drug entrapment efficiency. Particle size was 
also increased from 209±3.9 nm (NPs) to 213±1.9 nm, 
(conjugated NPs). The reduction in zeta potential from NPs 
(−23.03±1.6 mV) to conjugated NPs (−14.4±2.1 mV) was 
observed. High absolute value of zeta potential indicates 
higher electric charge on the surface of the drug-loaded 
NPs, (Table 1). 
 
Table 1: Parameters for formulation of plain and combined Nanoparticles 
S. 
No. 
Formulation 
Average 
Particle 
Size (nm) 
PDI 
Entrapment 
efficiency (%) 
Zeta 
potential 
1 Plain Nanoparticles 209±3.9 0.342±0.062 50.37±5.9 -23.03±1.6 
2 
NPs of conjugated 
polymer 
213±1.9 0.318±0.153 52.02±1.9 -14.4±2.1 
Mean ± SD (n = 3) 
a b 
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To perform in vivo studies firstly, the NPs and plain insulin 
powder were filled in hard gelatin capsules (Capsule No. 5) 
which were coated with enteric polymer Eudragit S 100. 
The experimental diabetes was induced with 
streptozotocin in rabbits.  As diabetic rabbits were selected 
for the study which might have died if continuously fasted, 
so standard feed were given to the animals of all groups at 
4, 12 and 24 h of study, which raised BGL values at 6th h 
and 14th h till 2 h post-feed.  
Blood glucose level of group 1 animals showed 
hyperglycemia consistently throughout the study. While 
oral administration of insulin to Group 2 animals did 
not produce significant lowering of blood glucose level. 
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Figure 7: Blood Glucose Profile at various time intervals on oral administration of different formulations compared with 
subcutaneous administration of marketed preparation. 
 
Figure 8: Insulin plasma level at various time intervals on oral administration of different formulations compared with 
subcutaneous administration of marketed preparation 
*= diet given 
Thermal Analysis was performed by DSC .Thermograms were obtained using a Shimadzu DSC-50 system 
(Shimadzu, Kyoto, Japan). Samples were lyophilized, 2.0 mg of lyophilized powder crimped in a standard 
aluminium pan and heated from 20 to 350C at a heating constant rate of 10C/min under constant 
purging of nitrogen at 20 mL/min 
 
Figure 9: DSC Thermogram of (a) Pure Insulin, (b) insulin Loaded NPs, (c) insulin Loaded conjugated NPs. 
When oral suspension of insulin loaded PLGA 
nanoparticles was given the blood glucose level is not 
reduced from 265.4±8.5 mg/dL at initial two hours which 
further reduced to 246.6±2.4 mg/dL within 4 h, the blood 
glucose further decreased to 198.7±7.1 mg/dL value at 8th 
h, depicting the hypoglycaemic effect prolonging for 4 h 
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and this blood glucose level increased to 152.7±5.3 mg/dL 
after 12 h of administration (Fig.10), The ligand conjugated 
formulation on oral administration produced 
hypoglycaemic effect within 4 h of administration, i.e, 
blood glucose level is reduced from 277.7±5.3 mg/dL at 
initial two hours further reduced to 216.9±1.9 mg/dL. The 
hypoglycaemic effect prolonged till 12 h of oral 
administration. Compared with formulation loaded with 
the drug, the valine conjugated nanoparticles produced a 
sustained hypoglycaemic response till 12 h than 8 h. 
The mean extraction eﬃciency results of insulin from 
rabbit plasma at concentrations of 100, 200, 300 and 500 
ng/mL were found to be 85.01, 91.51, 84.68 and 90.54%. 
The mean recovery for I.S. was 85.72 ± 1.62%.  
DISCUSSION 
PLGA was conjugated with L-valine which acts as navigator 
and enhance the particle uptake. The molecular 
conjugation of PLGA with hydrophilic drugs, in particular 
peptides and proteins, has been scarcely found in the 
literature due to absence of reactive functional groups in 
the PLGA chain backbone. Uncapped and hydrophilic PLGA 
that has a carboxylic acid group at its terminal end, 
however, can be readily conjugated to various drug 
compounds. The conjugation between PLGA and valine 
was confirmed by IR spectroscopy.  
The conjugation of L-valine with PLGA polymer was 
proved by FTIR. In PLGA, a peak at 3396 cmˉ1 was found 
which indicated the bending of free N-H stretching, peak at 
1749.3 cmˉ1  represents C=O stretch, peak at 1402.7 cmˉ1  
represents N-H bending. In valine-PLGA conjugate, peak at 
1718 cm-1 represents C=O stretch of valine-PLGA 
conjugate, peak at 1211,1185 cmˉ1  represents C-O stretch, 
peak at 1538.3 cmˉ1 represents N-H bending and peak at 
3381/3217 cmˉ1  represents N-H stretch which prove the 
conjugation of NH2 group of L-valine with COOH group of 
PLGA.  
The single emulsion method is confined to the entrapment 
of lipophilic compounds; whereas hydrophilic compounds 
tend to show diffusion and partitioning from the dispersed 
oil phase into the continuous aqueous phase. Therefore, for 
an encapsulation of hydrophilic agents such as insulin 
double emulsion process was used. A buffered aqueous 
solution of the compound, additionally sonication is added 
to form the first microfine water-in-oil (w/o) solution. This 
emulsion was added gently with stirring into a second 
aqueous phase containing stabilizers (PVA) to form a 
water-in-oil-in-water (w/o/w) emulsion. The organic 
solvent is removed by evaporation or extraction. This 
double emulsion process is best suited to encapsulate 
hydrophilic drugs like peptides and proteins and also 
suitable for enhancing protein stability.8 
PLGA (poly lactic co glycolic acid) was used for the 
preparation of nanoparticles (NPs). It is  biodegradable 
and biocompatible, it degrades by hydrolysis of its ester 
linkages in the presence of water into two monomers lactic 
acid and glycolic acid which under normal physiological 
conditions, are by-products of various metabolic pathways 
in the body. PLGA with 50:50 monomers as ratio exhibits 
faster degradation (about two months). In addition, 
polymers that are end-capped with esters (as opposed to 
the free carboxylic acid) demonstrate longer degradation 
half-lives and molecular weight 17000 was used in the 
preparation of nanoparticles. It has very good mechanical 
properties and long shelf life. For this study uncapped 
PLGA was used which is having free carboxylic acid group 
(COOH) for the conjugation. 
The endothermic peak diminishes in the drug loaded 
preparation indicating the entrapment of drug in the NPs 
and conjugated NPs. 
The SEM and TEM photomicrographs showed the spherical 
morphology of the nanoparticles. TEM was used to 
investigate the shape of NPs. TEM photographs suggested 
that all NPs and NPs of conjugated polymer were spherical 
in shape and in nanometric range.  
It was anticipated from the study of in vitro drug release 
profile that the formulation gives no detectable release at 
initial two hours that must be due to enteric polymer 
coating. The vitro release studies of NPs showed a percent 
cumulative drug release of 48.587.3% after 24 h whereas 
conjugated nanoparticles showed cumulative drug release 
of 45.81±8.7% after 24 h. A significant decline in the 
percentage cumulative release rate of insulin from 
conjugated nanoparticles was observed in comparison to 
NPs that indicated that coupling of valine to PLGA slows 
down the release of drug from the nanoparticles and 
thereby imparts a sustained release nature.  
The NPs and plain insulin powder were filled in hard 
gelatin capsules (Capsule No. 5) which were coated with 
enteric polymer Eudragit S 100 to protect drug from the 
harsh environment of stomach. The experimental diabetes 
was induced with streptozotocin in rabbits.  As diabetic 
rabbits were selected for the study which might have died 
if continuously fasted, so standard feed were given to the 
animals of all groups at 4, 12 and 24 h of study, which 
raised BGL values at 6th h and 14th h till 2 h post-feed.  
Blood glucose level of group 1 animals showed 
hyperglycemia consistently throughout the study as they 
were experimentally induced diabetic and not treated. 
While oral administration of insulin to Group 2 animals 
did not produce significant lowering of blood glucose 
level as the insulin probably degraded in GIT lumen and 
impermeability of insulin through GIT membrane. 
When oral suspension of insulin loaded PLGA 
nanoparticles was given, the blood glucose level was not 
reduced at initial two hours due to enteric coated polymer 
which further reduced within 4 h, the blood glucose further 
decreased to 198.7±7.1 mg/dL value at 8th h, depicting the 
hypoglycaemic effect prolonging for 4 h and this blood 
glucose level increased to 152.7±5.3 mg/dL after 12 h of 
administration, indicating that the insulin bearing 
polymeric nanoparticles produced sustained 
hypoglycaemic response up to 24 hours. The optimum 
wavelength for detecting insulin with adequate sensitivity 
was found to be at 214 nm. The elution time of insulin was 
16.50 min. 
An eﬃcient recovery of insulin and I.S. from plasma was 
achieved using a solvent mixture of dichloromethane and 
n-hexane (1:1 v/v) as an extraction solvent. When 
dichloromethane was used alone as an extraction solvent, 
the recovery of insulin was about 60% but with the 
mixture of dichloromethane and n-hexane, the recovery 
improved to about 89%. 
CONCLUSION 
L-valine-conjugated PLGA-nanoparticles were prepared 
using double emulsion solvent evaporation method. The 
Vishwakarma et al                                                                                         Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):93-101  
ISSN: 2250-1177                                                                                  [101]                                                                                 CODEN (USA): JDDTAO 
insulin bearing nanoparticles were also studied for FTIR, 
size, drug entrapment efficiency, zeta potential, SEM, TEM, 
in vitro insulin release, in vivo release. The FTIR studies 
proved the conjugation of NH2 group of L-valine with 
COOH group of PLGA. TEM & SEM photographs suggested 
that all NPs and NPs of conjugated polymer were spherical 
in shape and in nanometric range. The Entrapment 
Efficiency was studied using uncapped PLGA was used 
which is having free carboxylic acid group (COOH) for the 
conjugation. The endothermic peak diminishes in the drug 
loaded preparation indicating the entrapment of drug in 
the NPs and conjugated NPs. The reduction in size of the 
particle caused a decrease in zeta potential value, as High 
absolute value of zeta potential indicates higher electric 
charge on the surface of the drug-loaded NPs. The in vitro 
drug release profile that the formulation showed no 
detectable release after 24 h which indicated the coupling 
of valine to PLGA that slows down the release of drug from 
the nanoparticles and thereby imparts a sustained release 
nature. An eﬃcient recovery of insulin and I.S. from plasma 
was achieved using a solvent mixture of dichloromethane 
and n-hexane (1:1 v/v) as an extraction solvent. The in Vivo 
studies revealed that, when oral suspension of insulin 
loaded PLGA Nanoparticles was given, the insulin bearing 
polymeric Nanoparticles produced sustained 
hypoglycaemic response up to 24 hours. Thus, the L-valine 
conjugated NPs bearing insulin were successfully 
formulated and evaluated. Hence it can be assumed that 
they are the most suitable way for the transportation of 
insulin across the intestine on oral administration. 
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